**Supplementary Table 1.** Patient demographics and baseline characteristics – subanalysis population.

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Patients <60 years****(n = 782)** | **Patients ≥60 years****(n = 415)** |
| **Gender, n (%)** |
| Female | 778 (99) | 410 (99) |
| Male | 4 (1) | 5 (1) |
| **Age, years** |
| Mean (SD) | 48.0 (7.45) | 67.1 (5.12) |
| Median | 49.0 | 66.0 |
| Min–max | 26–59 | 60–79 |
| **Tumor type, n (%)** |
| Breast | 782 (100) | 415 (100) |
| **ECOG PS, n (%)** |
| 0 | 603 (77.1) | 261 (62.9) |
| 1 | 155 (19.8) | 139 (33.5) |
| 2 | 24 (3.1) | 15 (3.6) |
| **Therapy type\*, n (%)** |
| Adjuvant | 384 (49.1) | 260 (62.7) |
| Neoadjuvant | 386 (49.4) | 147 (35.4) |
| Palliative | 10 (1.3) | 5 (1.2) |
| Missing | 2 (0.3) | 3 (0.7) |
| **Emetic risk of chemotherapy†, n (%)**  |
| AC-HEC | 782 (100) | 415 (100) |

\*Patients receiving multiple therapies at cycles 1, 2, and 3 could be assigned to multiple categories.
†Patients not documented in the eCRF were excluded.
AC, anthracycline plus cyclophosphamide; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HEC, highly emetogenic chemotherapy; max, maximum; min, minimum; SD, standard deviation.